Parainfluenza virus (PIV) is an important cause of acute respiratory illness in children; however, scarce data have been reported on the clinical significance of PIV co-detection with other viruses.Between 12/01/2016 and 03/31/2020, we conducted active surveillance for children who presented to the emergency department or were hospitalized with fever or respiratory symptoms at seven U.S. medical centers within NVSN. Demographic and clinical data were collected through parent/guardian interviews and chart abstraction. Nasal and/or throat swabs were tested for PIV types 1–4; respiratory syncytial virus (RSV); rhinovirus or enterovirus (RV/EV); adenovirus (AdV); common cold coronaviruses (ccCoV) 229E, HKU1, NL63, and OC43; SARS-CoV-2; influenza (Flu) A, B, and C; and human metapneumovirus (hMPV). We used a generalized linear mixed-effects model with a logit link to compare the odds of hospitalization between children < 2 years old with PIV-only detection and those with PIV co-detection. Our analysis included age, underlying conditions, and preterm birth as fixed effects and study site as a random effect.Table 1.Comparison of the demographic and clinical characteristics of children with PIV-only detection and those with respiratory virus co-detection, NVSN, 2016–2020.Figure 1.Relative frequencies of respiratory viruses co-detected with PIV in U.S. children <2 years old, stratified by highest* level of care received, NVSN, 2016–2020. Abbreviations: PIV, parainfluenza virus; RV/EV, rhinovirus or enterovirus; RSV, respiratory syncytial virus; AdV, adenovirus; ccCoV, common cold coronaviruses; hMPV, human metapneumovirus; Flu, influenza.Table 1. Notably, children with PIV co-detection were more likely to attend daycare, preschool, or school. Compared with PIV-only detection, the odds of hospitalization were higher for PIV/RSV  and PIV/Flu , lower for PIV/AdV, and comparable for the remaining pairs including PIV/RV/EV, the most common co-detection.Of 17,850 children tested for PIV, 1,641 (9.2%) were positive: 1,116 (68.0%) with PIV-only detection and 525 (32.0%) with PIV co-detected with at least one other virus. The demographic and clinical characteristics of children with single PIV detection and those with co-detection are compared in Table 2.Multivariable logistic regression model of hospitalization in U.S. children with PIV-only detection and those with PIV co-detection with one other respiratory virus, NVSN, 2016–2020.The association between PIV co-detection and odds of hospitalization was virus-specific for children < 2 years old. Further investigation is warranted to determine if these findings are driven by RSV and influenza's impact on illness severity or if they are indicative of a potential virus–virus interaction that exacerbates PIV disease.Janet A. Englund, MD, Ark Biopharma: Advisor/Consultant|AstraZeneca: Advisor/Consultant|AstraZeneca: Grant/Research Support|GlaxoSmithKline: Grant/Research Support|Meissa Vaccines: Advisor/Consultant|Merck: Grant/Research Support|Moderna: Advisor/Consultant|Moderna: Grant/Research Support|Pfizer: Advisor/Consultant|Pfizer: Grant/Research Support|Sanofi Pasteur: Advisor/Consultant John V. Williams, MD, Merck: Grant/Research Support|Quidel: Board Member Marian G. Michaels, MD, MPH, Merck: Grant/Research Support|Viracor: Grant/Research Support Elizabeth P. Schlaudecker, MD, MPH, Pfizer: Grant/Research Support|Sanofi Pasteur: Advisor/Consultant Mary A. Staat, MD, MPH, CDC: Grant/Research Support|Cepheid: Grant/Research Support|Merck: Grant/Research Support|NIH: Grant/Research Support|Pfizer: Grant/Research Support|Up-To-Date: Honoraria Pedro A. Piedra, MD, Ark Bioscience: Advisor/Consultant|Ark Bioscience: Grant/Research Support|GSK: Grant/Research Support|Icosavax: Advisor/Consultant|Icosavax: Grant/Research Support|Mapp Biologics: Grant/Research Support|Meissa Vaccines: Grant/Research Support|Moderna: Advisor/Consultant|Novavax: Advisor/Consultant|Novavax: Grant/Research Support|Sanofi-Pasteur: Grant/Research Support|Shionogi: Advisor/Consultant|Shionogi: Grant/Research Support|Takeda: Advisor/Consultant Rangaraj Selvarangan, BVSc, PhD, D(ABMM), FIDSA, FAAM, Abbott: Honoraria|Altona Diagnostics: Grant/Research Support|Baebies Inc: Advisor/Consultant|BioMerieux: Advisor/Consultant|BioMerieux: Grant/Research Support|Bio-Rad: Grant/Research Support|Cepheid: Grant/Research Support|GSK: Advisor/Consultant|Hologic: Grant/Research Support|Lab Simply: Advisor/Consultant|Luminex: Grant/Research Support Natasha B. Halasa, MD, MPH, Merck: Grant/Research Support|Quidell: Grant/Research Support|Quidell: donation of kits|Sanofi: Grant/Research Support|Sanofi: vaccine support Geoffrey A. Weinberg, MD, Merck & Co: Honoraria


Correction to: Pediatric Cardiology (2022) 44:312–324 10.1007/s00246-022-03074-wIn the original publication of the article, only family names were mentioned.The authors’ full names are:Raphael Joye, Maurice Beghetti, Julie Wacker, Iliona Malaspinas, Maya Bouhabib, Angelo Polito, Alice Bordessoule & Dipen C. Shah.This has been corrected in this paper.


The correct name is: Sheikh Shoib. The correct citation is: Swed S, Shoib S, Fathy Hassan NAI, Almoshantaf MB, Alkadi SMS, AbdelQadir YH, et al. (2022) Stigmatizing attitudes towards depression among university students in Syria. PloS ONE, 17(9), e0273483. haidara.bohsas@gmail.com) Hidar Alibrahim  Shahm alsakka  Mhd Noor Tahawi  Mulham Al-Zahran  Joudi Anadani  Nader Ebrahim The data collection group is missing from the Acknowledgments section. The Acknowledgments should list the following individuals from the data collection group: Haidara Bohsas (Faculty of Medicine, Aleppo University, Aleppo, Syria;


Rhagovelia Mayr, 1865 , known as riffle bugs, includes more than 400 species and is commonly found in tropical lotic environments, including coastal marine habitats, such as mangroves and estuaries. Due to the elevated number of species, the fauna from the Americas has been divided into several groups, which facilitates taxonomic studies. Amongst them, the itatiana group currently includes two species from the Greater Antilles and five from south-eastern and southern Brazil. Despite the many taxonomic studies developed during the past few decades, new species of Rhagovelia are still being discovered in several areas of the continent, including the Atlantic Forest of eastern Brazil.Rhagoveliabispoi sp. n. is described, illustrated and compared with similar congeners. The new species belongs to the itatiaiana group and can be diagnosed by the uniformly black mesonotum, the presence of a tuft of setae medially on male abdominal sternum VII, the armature of the male hind femur and the distinctive shape of the paramere. In addition, we present new records of R.trepida Bacon, 1948 from the States of Paraná and Santa Catarina and a key to the species of the itatiaiana group recorded from Brazil. Veliidae  is a worldwide distributed group of semi-aquatic bugs that is especially rich in the Neotropics , containing almost 200 described American species and being commonly found in lotic environments, sometimes in groups of hundreds of individuals  and five complexes (monophyletic)  . Althougn convex .abrupta grade, namely cali, itatiaiana, lucida, secluda and torquata. Amongst them, the itatiaiana group is recognised by the general blackish colouration with distinctively contrasting orange markings on the pronotum and abdominal laterotergites; the forewing with four closed cells, of which the distalmost two extend into the distal half of the wing , while the other five are restricted to south-eastern and southern Brazil ; Laboratório de Biologia Aquática, Universidade Estadual Paulista Júlio de Mesquita Filho, Assis, Brazil (LABIA); Museu Nacional, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil ; Museu de Zoologia, Universidade de São Paulo, São Paulo, Brazil (MZUSP); and National Museum of Natural History, Smithsonian Institution, Washington D.C., USA (NMNH). Methods and terminology follow the standards set in the latest revision of the genus  and subsDigital photographs of the specimens deposited in the CEIOC were obtained using a Leica M205 C stereomicroscope coupled with a Leica DFC450 C digital camera, using the software Leica LAS 4.8.0 for capturing and stacking images. Specimens deposited in the NMNH were photographed with a Cannon EOS 5D digital camera and combined into multi-focal images using Visionary Digital Software. Maps were produced using the software Qgis 2.6.1.CAAFC51C-818B-5DBD-B141-916E801FBA02090D3712-A5EB-4E20-A8A9-035805C091CEType status:Holotype. Occurrence: individualCount: 1; sex: apterous male; occurrenceID: 74FA7FE9-7843-5F2B-AB9A-B0CD6C8FB338; Taxon: scientificNameID: Rhagoveliabispoi; order: Hemiptera; family: Veliidae; Location: continent: South America; country: Brazil; stateProvince: São Paulo; municipality: Iporanga; locality: Parque Estadual Intervales, Riacho Roda D’Água; decimalLatitude: -24.2714; decimalLongitude: -48.4222; geodeticDatum: WGS84; Event: verbatimEventDate: 14.XII.2014; eventRemarks: P.C. Bispo leg.; Record Level: type: PhysicalObject; collectionCode: CEIOC 82833; basisOfRecord: PreservedSpecimenType status:Paratype. Occurrence: individualCount: 18; sex: 7 apterous males, 11 apterous females; occurrenceID: DEBD6A2D-8E0E-54AF-852E-FDCE4CE6459C; Taxon: scientificNameID: Rhagoveliabispoi; order: Hemiptera; family: Veliidae; Location: continent: South America; country: Brazil; stateProvince: São Paulo; municipality: Iporanga; locality: Parque Estadual Intervales, Riacho Roda D’Água; decimalLatitude: -24.2714; decimalLongitude: -48.4222; geodeticDatum: WGS84; Event: verbatimEventDate: 14.XII.2014; eventRemarks: P.C. Bispo leg.; Record Level: type: PhysicalObject; collectionCode: CEIOC 82834; basisOfRecord: PreservedSpecimenMeasurements. See Table Apterous male (Figs 34ale Figs , 3a, 4b.e Figs 34a, c. MesHead short, velvety, with a few long setae anteriorly and adjacent to mesal eye margin. Antennae covered by short brown setae; antennomeres I–II also with a few thicker, longer setae. Antennomeres I–III cylindrical; I curved laterally; IV fusiform. Labium wide, reaching base of mesosternum. Jugum and adjacent portion of proepisternum without black denticles. Pro-, meso- and metanota densely covered by short setae, with longer setae laterally. Pronotum longer than dorsal eye length, shorter than three times exposed portion of mesonotum, with posterior margin convex. Pro-, meso- and metapleura with a few long setae. Legs covered by brown setae, more densely on trochanters, femora and tibiae; femora and tibiae also with rows of longer, thicker, black setae. Fore tibia slightly widened distally, weakly concave near apex. Trochanters without spines. Hind femur with row of 10–11 short spines on proximal third, the last one sometimes slightly longer than the others; distal 2/3 with two parallel rows of spines, dorsalmost row with 11–12 spines, the first and tenth or eleventh larger than the others, ventralmost row with 5 short spines (Figs 13114Apterous female (Fig. ale Fig. . Similarale Fig. , with smale Fig. a, b. Hinale Fig. a, b. Abdale Fig. a. Abdomiale Fig. b.Variation. Fore tibia, hind femur and hind tibia less robust in some males (Table es Table . Concaviitatiaiana group, Rhagoveliabispoi sp. n. is more similar to R.itaiaiana Drake, 1953, R.macta Drake & Carvalho, 1955 and R.trepida Bacon, 1948, with which it shares the presence of a medial tuft of setae on the anterior portion of male abdominal sternum VII. However, males of the new species have the main row of spines on the hind femur with two large spines separated by nine or ten smaller spines (Figs 13R.itatiaiana and R.trepida, the row consists of a large spine followed by spines gradually decreasing in length towards the apex (as in Fig. 3R.macta; however, they can be distinguished by the mesonotum entirely black in the former (Fig. 154Within the The new species is named in honour of Dr. Pitágoras da Conceição Bispo, who collected the specimens and also advised CFBF during her doctoral studies.Bacon, 1948F538DD43-B582-5A4B-8638-CE446312800AType status:Other material. Occurrence: individualCount: 13; sex: 5 apterous males, 8 apterous females; occurrenceID: BBB1BEF9-3300-5CBC-9427-DF9ED2759C9E; Taxon: order: Hemiptera; family: Veliidae; Location: continent: South America; country: Brazil; stateProvince: Paraná; municipality: Balsa Nova / Palmeira; locality: Rio das Pombas, BR-376; decimalLatitude: -25.44; decimalLongitude: -49.79; geodeticDatum: WGS84; Event: verbatimEventDate: IV-2017; Record Level: type: PhysicalObject; collectionCode: LABIA; basisOfRecord: PreservedSpecimenType status:Other material. Occurrence: individualCount: 10; sex: 6 apterous males, 4 apterous females; occurrenceID: 37C85CD3-712B-5EC0-B380-3613CE195459; Taxon: order: Hemiptera; family: Veliidae; Location: continent: South America; country: Brazil; stateProvince: Santa Catarina; municipality: Blumenau; locality: Parque Nacional da Serra de Itajaí, Parque das Nascentes, stream near Lagoa Negra; decimalLatitude: -27.058; decimalLongitude: -49.089; geodeticDatum: WGS84; Event: verbatimEventDate: IV-2017; eventRemarks: P.C. Bispo leg.; Record Level: type: PhysicalObject; collectionCode: LABIA; basisOfRecord: PreservedSpecimenType status:Other material. Occurrence: individualCount: 12; sex: 5 apterous males, 7 apterous females; occurrenceID: B21C9802-44CE-5A56-84F6-BAD4235E880A; Taxon: order: Hemiptera; family: Veliidae; Location: continent: South America; country: Brazil; stateProvince: Santa Catarina; municipality: Rio Negrinho; locality: Rio dos Bugres; decimalLatitude: -26.3722; decimalLongitude: -49.5200; geodeticDatum: WGS84; Event: verbatimEventDate: 31.III.2020; eventRemarks: T. Polizei leg.; Record Level: type: PhysicalObject; collectionCode: MZUSP; basisOfRecord: PreservedSpecimenThis species is endemic to the Brazilian Atlantic Forest and is distributed from the coastal areas of the States of Rio de Janeiro and São Paulo to the northern portion of the State of Rio Grande do Sul. It has been seldom collected and reported in only three previous studies . Above, 6


Atkinsoniella Distant, 1908 includes 99 valid species worldwide. Here, three new species from China are described and illustrated: Atkinsoniellastenopyga, A.wangi, and A.yingjiangensisspp. nov. An updated checklist of the known Atkinsoniella species worldwide based on the data of previous literature and studied materials is also provided. All the type specimens of three new species are deposited at the Institute of Entomology, Guizhou University, Guiyang, China.The sharpshooter genus  Atkinsoniella is a relatively large genus of the subfamily Cicadellinae. It was established by A.decisa (type species) and A.maculata. Atkinsoniella, proposed 15 new combinations and 13 synonyms, described 10 new species, and confirmed 26 valid species of this genus. Thereafter, new species were described successively.The genus Atkinsoniella species from China, including 33 new species, two Chinese new records, 12 new synonyms, and proposed Curvufacies Kuoh, 1993 as a new synonym of Atkinsoniella. Subsequently, 2 new species from China and Pakistan were described  and Yunnan-Guizhou Plateau (Yunnan Province) of China are provided. The checklist of all known Atkinsoniella species worldwide and the three new species is updated.To date, 99 valid species were described worldwide, of which 89 species occurred in China, and a few were scattered in Bay of Bengal, Bhutan, India, Indonesia, Kingdom of Bhutan, Laos, Malay Islands, Malaysia, Myanmar, Nepal, Pakistan, Philippines, Thailand, and Vietnam . In thisGUGC).The specimens were collected by sweeping (27–35 sweeps per collecting event) on shrubs and weeds using 2.5 m insect sweep nets on day-light and off-set sun by using a 500W high-pressure mercury lamps; all materials were preserved in absolute ethanol and stored at -20 °C in the laboratory. The abdomens of specimens were detached and soaked in 10% NaOH solution, boiled for 1–3 min, rinsed with water to remove traces of NaOH, and transferred to glycerol for further dissection, photography and preservation. The habitus and male genitalia were photographed using a KEYENCE VHX-6000 digital camera and a Nikon Eclipse Ni-E microscope, respectively. Adobe Photoshop 2020 was used to edit compiled photos. The length of the body was measured from the vertex to the rear of the forewings using a KEYENCE VHX-6000 digital camera. The morphological terminology is adapted from Taxon classificationAnimaliaHemipteraCicadellidaeDistant, 19083E2E5085-7F3F-59E9-B2C3-D12DAF74212FAtkinsoniella Distant, 1908: 235.Soibanga Distant, 1908: 236.Curvufacies Kuoh, 1993: 38.Atkinsonielladecisa Distant, 1908.Palaearctic, Oriental.Taxon classificationAnimaliaHemipteraCicadellidaeJiang & Yangsp. nov.899B50EA-1F85-58FD-BB79-849F315A9FF1https://zoobank.org/325305A3-840F-480C-B5CF-1F5FC86957C5Crown and thorax canary yellow and greyish white in dorsal view; a small subcircular black spot at apex of head and basal margin medially, and interocular width 2× wider than long; eyes fuscus; ocelli greyish white with narrow black border; forewing light orange; face off-white, frontoclypeus median with a broad yellowish white longitudinal; thorax and abdomen yellowish white in ventral view; legs orangish with pretarsi black or dark brown.Anterior margin of crown broadly rounded and convex, and median length of crown shorter than interocular width. Ocelli nearest to midline and posterior margin than eyes, lateral area concave, each ocellus further from the other than to the adjacent eye. Face with frontoclypeus flat medially; muscle impressions distinct and extend to the tip of crown; clypeal sulcus blurred in the median; anteclypeus longitudinally gibbous. Pronotum wider than head, anterior margin arcuately convex, posterior margin with medially concave. Scutellum with medial transverse depression. Forewings with distinct apical membranous area, base of second cells more proximal than third cells transversely.Male pygofer narrowly rounded posteriorly and convex dorsally, posterior half long scoop-shaped with macrosetae; pygofer processes slender and strongly sclerosed, base broad with microsetae; bending dorsad from basal one-third and then extending straightly, tip acute and exceeding dorsal margin posteriorly of pygofer. Subgenital plates in ventral view convex and short with one row of macrosetae uniseriate obliquely, long dense mid microsetae, and posterior half with long and short microsetae dispersedly with apex rounded. Aedeagus stubby and straight, with posterior margin truncate and dorsal margin concave subbasally, one protuberance at base ventrally articulating with paraphysis, and concave at the articulation with paraphysis apically; paraphysis long and thick, apical portion intumescent, apex bifurcated and articulating with aedeagus. Connective Y-shaped; style slender, with tip tapered and curved.stenopyga, referring a narrow pygofer shape.The specific epithet is the combined noun of stenos and tail from Greek, Length of male 7.8–8.0 mm.Holotype: ♂, Motuo, Tibet, China, 18 August 2020, coll. Xian-Yi Wang. Paratype, 1♂, same data as holotype.A.thaloidea Young, 1986, A.flavipenna Li & Wang, 1992, A.uniguttata Li, 1993, and A.bowa Yang, Meng & Li, 2017 in appearance, but can be easily differentiated from these species by the following characteristics: (1) pygofer slender; (2) aedeagus stubby with posterior margin truncate; and (3) two pointed dentate protrusions at the apex of the paraphysis incurved dorsally and embracing.This species is similar to China (Tibet).Taxon classificationAnimaliaHemipteraCicadellidaeJiang & Yangsp. nov.15EA130B-EC1B-5D7C-94B7-F133A2B19756https://zoobank.org/89195CDF-6EDC-4BF0-AEDB-A7508F9A9795Crown, thorax and forewings orange in dorsal view; crown with a black spot at anterior margin medially and a smaller black spot at posterior margin medially; eyes off-white or dark brown; ocelli off-white with black border; forewings orange, with apical membranous area darker; face, thorax and abdomen in ventral view, legs orange.Crown with anterior margin rounded prominently, and interocular width 2× wider than long. Ocelli nearest to midline and posterior margin than eyes, lateral area concave, each ocellus slightly further from the other one than to the adjacent eye. Face with a nodular protrusion in the center, frontoclypeus flat medially, muscle impressions distinct and extending to the tip of crown, clypeal sulcus distinct medially. Pronotum broader than head, anterior margin protruding roundly, posterior margin with medially concave. Scutellum convex anterior and posterior to transverse depression, with transverse depression arcuate, a large black spot near each basal angle in some specimens. Forewings with four apical cells, the base of the second cells more basal than third cells transversely, apical membranous area distinct.Male pygofer slender, posterior portion tilted dorsad and posterior margin round, posterior half with macrosetae; pygofer process lamellate, base with several macrosetae, bending dorsad from basal one-third, posterior one-third portion lamellate broadly and tortile backward and apex acute. Subgenital plates broad at base, posterior half narrow and bent dorsally, one row of macrosetae uniseriate obliquely in the median, lateral area with long dense microsetae, apical half with short microsetae dispersedly. Aedeagus broad at base, posterior half constricted and tilted dorsad, tip swordlike, ventral margin protuberant at the articulation with the tip of paraphysis and concave subbasally; paraphysis dilated apically and constricted subapically, apex bifurcated and articulating with aedeagus. Connective V-shaped. Style wide at base and tapered at tip, apex acute.The new species is named after the family name of collector Xian-Yi Wang.Length of male 7.9–8.0 mm.Holotype: ♂, Tongmai, Tibet, China, 18 August 2020, coll. Xian-Yi Wang. Paratypes, 1♂ (light trapped) +11♂♂, same data as holotype; 1♂, Tongmai, Tibet, China, 19 August 2020, light trapped, coll. Xian-Yi Wang.A.curvata Zhang & Kuoh in appearance and male genitalia, but can be distinguished from the latter by the following characteristics: (1) crown with a black spot in the median of the anterior margin, and the smaller black spot at the basal margin medially narrower than the width between the ocelli, but the latter only with a large V-shaped black spot below the ocelli; (2) pygofer of the new species slender overall, with posterior margin rounded, while pygofer of the latter slender at apical one-third, with the posterior margin truncate; (3) aedeagus of the new species tilted dorsally at the posterior half, while aedeagus of the latter straight overall; and (4) connective of the new species V-shaped, but connective of the latter Y-shaped.This species is similar to China (Tibet).Taxon classificationAnimaliaHemipteraCicadellidaeJiang & Yangsp. nov.C2F1BBF5-AAE6-5C59-9787-451AE04E75A4https://zoobank.org/6FD2EA20-B2DA-442B-B50E-A35F91051243Head and thorax dark orange in dorsal view; crown with a black spot at the anterior margin medially, basal margin with a black spot below each ocellus, and lateral margin with a black spot anterior to each antennal ledge; eyes dark brown; ocelli gray; pronotum with two small black spots abreast in the center, and posterior area with two large black spots transversely; scutellum with a large triangular black spot at each basal, and the base of the two spots linked; forewings black, with three longitudinal grayish white stripes, apical membranous area dark brown; face dark orange; thorax black in ventral view; legs grayish white.Crown with anterior margin convex roundly, median length of crown approximately equal to half of interocular width, concave lateral area of ocelli. Ocelli located at the line of anterior eyes, each ocellus slightly further from the other one than to the adjacent eye. Face with frontoclypeus flat in the median, muscle impressions and clypeal sulcus distinct. Pronotum wider than head, anterior margin convex roundly and posterior margin concave. Scutellum with transverse depression slightly posterior to the median. Forewings with apical membranous area not obvious, base of the second and third cells almost aligned transversely.Male pygofer narrowly rounded posteriorly, tip oblique dorsally, dorsal margin with lamellar prominence at basal one-third, with macrosetae in posterior half and microsetae in the median dispersedly; pygofer processes with microsetae at base, arising basiventrally on each side and extending dorsolateral posteriorly of pygofer, apex acute and exceeding posterior margin of pygofer. Subgenital plates broad at base and constrictive at tip, with one row of macrosetae uniseriate obliquely, long microsetae on lateral area, short microsetae on posterior half. Aedeagus slender, bent dorsally at tip and curved ventral, ventral margin with a horned protuberance basically articulating with paraphysis; paraphysis wide subapically, with two lamellate bulges at tip, apex uncinate and articulating with aedeagus. Connective Y-shaped. Style narrow at posterior portion, apex curved and exceeding the tip of connective.The name of the new species is derived from Yingjiang where the type specimens were collected.Length of male 8.0–8.1 mm.Holotype: ♂, Yingjiang, Yunnan, China, 25 June 2019, coll. Tie-Long Xu. Paratypes, 2♂♂, same data as holotype.A.limba Kuoh, 1991 in male genitalia, but markedly differ in the following characteristics: (1) pronotum with two small black spots abreast in the center and two large black spots transversely at posterior area; (2) apex of the pygofer process exceeding the posterior margin of the pygofer; (3) aedeagus concave obviously at the ventral margin basally; and (4) paraphysis inflated subapically and posterior margin Λ-shaped in ventral view.This species is similar to China (Yunnan).Atkinsoniellaalbimacula Yang & Li, 2002Atkinsoniellaalbimacula Yang & Li, 2002a: 556.Distribution. China (Yunnan).Atkinsoniellaalbipenna Yang, Meng & Li, 2017Atkinsoniellaalbipenna Yang, Meng & Li, 2017: 219.Distribution. China .Atkinsoniellaalcmena Tettigoniellaalcmena Distant, 1908: 219.Atkinsoniellaalcmena (Distant): Young, 1986: 96.Distribution. China (Tibet), India.Atkinsoniellaalternata Young, 1986Atkinsoniellaalternata Young, 1986: 100.Distribution. China .Atkinsoniellaangula Kuoh, 1992Atkinsoniellaangula Kuoh, 1992: 126.Distribution. China .Atkinsoniellaanabella Young, 1986Atkinsoniellaanabella Young, 1986: 107.Distribution. Bhutan, India, Nepal.Atkinsoniellaatrata Yang, Meng & Li, 2017Atkinsoniellaatrata Yang, Meng & Li, 2017: 207.Distribution. China (Yunnan).Atkinsoniellaatronotata Kollaatronotata Distant, 1918: 10.Atkinsoniellaatronotata (Distant): Young, 1986: 96.Distribution. India.Atkinsoniellaaurantiaca Cai & Kuoh, 1995Atkinsoniellaaurantiaca Cai & Kuoh, 1995: 89.Distribution. China .Atkinsoniellabeaka Yang, Meng & Li, 2017Atkinsoniellabeaka Yang, Meng & Li, 2017: 218.Distribution. China (Yunnan).Atkinsoniellabella Tettigoniabella Walker, 1851: 778.Atkinsoniellabella : Young, 1986: 96.Distribution. India, Nepal.Atkinsoniellabiundulata Meng, Yang & Ni, 2010Atkinsoniellabiundulata Meng, Yang & Ni, 2010: 42.Distribution. China (Yunnan).Atkinsoniellabowa Yang, Meng & Li, 2017Atkinsoniellabowa Yang, Meng & Li, 2017: 206.Distribution. China (Yunnan).Atkinsoniellabrevistyla Yang & Li, 2004Atkinsoniellabrevistyla Yang & Li, 2004: 757.Distribution. China .Atkinsoniellachangae Yang, Meng & Li, 2017Atkinsoniellachangae Yang, Meng & Li, 2017: 240.Distribution. China (Yunnan).Atkinsoniellacontrariuscula Cicadellacontrariuscula Jacobi, 1944: 44.Atkinsoniellacontrariuscula (Jacobi): Young, 1986: 97.Atkinsoniellafurcata Zhang & Kuoh, 1993: 15.Distribution. China .Atkinsoniellacurvata Zhang & Kuoh, 1993Atkinsoniellacurvata Zhang & Kuoh, 1993: 13.Distribution. China .Atkinsoniellacuspidata Meng, Yang & Ni, 2010Atkinsoniellacuspidata Meng, Yang & Ni, 2010: 45.Distribution. China (Yunnan).Atkinsoniellacyclops Tettigoniellacyclops Melichar, 1914: 127.Atkinsoniellacyclops (Melichar): Young, 1986: 97.Distribution. China , Indonesia, Nepal.Atkinsonielladactylia Yang & Li, 2000Atkinsonielladactylia Yang & Li, 2000: 410.Atkinsoniellatrinotata Cai & He, 2002: 147.Distribution. China .Atkinsonielladecisa Distant, 1908Atkinsonielladecisa Distant, 1908: 236.Distribution. India.Atkinsonielladivaricata Yang, Meng & Li, 2017Atkinsonielladivaricata Yang, Meng & Li, 2017: 205.Distribution. China .Atkinsonielladormana Li, 1992Atkinsonielladormana Li, 1992: 345.Distribution. China .Atkinsonielladubia Young, 1986Atkinsonielladubia Young, 1986: 104.Distribution. China (Tibet), Bhutan.Atkinsonielladuna Yang, Meng & Li, 2017Atkinsonielladuna Yang, Meng & Li, 2017: 236.Distribution. China .Atkinsoniellaexpanda Yang, Meng & Li, 2017Atkinsoniellaexpanda Yang, Meng & Li, 2017: 214.Distribution. China (Yunnan).Atkinsoniellafishtaila Yang, Meng & Li, 2017Atkinsoniellafishtaila Yang, Meng & Li, 2017: 221.Distribution. China (Hubei).Atkinsoniellafistular Naveed & Zhang, 2018Atkinsoniellafistular Naveed & Zhang, 2018: 286.Distribution. Pakistan.Atkinsoniellaflavilega Yang, Meng & Li, 2017Atkinsoniellaflavilega Yang, Meng & Li, 2017: 242.Distribution. China (Yunnan).Atkinsoniellaflavipenna Li & Wang, 1992Atkinsoniellaflavipenna Li & Wang, 1992: 95.Distribution. China .Atkinsoniellaflexa Kuoh, 1992Atkinsoniellaflexa Kuoh, 1992: 127.Distribution. China (Yunnan).Atkinsoniellafuripygofera Yang & Meng, 2011Atkinsoniellafuripygofera Yang & Meng in Yang, Meng & Li, 2011: 765.Distribution. China (Yunnan).Atkinsoniellafuscopenna Yang & Li, 2004Atkinsoniellafuscopenna Yang & Li, 2004: 756.Distribution. China (Tibet).Atkinsoniellagoosenecka Yang, Meng & Li, 2017Atkinsoniellagoosenecka Yang, Meng & Li, 2017: 222.Distribution. China .Atkinsoniellagrahami Young, 1986Atkinsoniellagrahami Young, 1986: 105.Atkinsoniellanigroscuta Zhang & Kuoh, 1993: 11.Atkinsoniellafurcula Yang & Li, 2002b: 40.Distribution. China .Atkinsoniellagregalis Kollagregalis Distant, 1908: 226.Atkinsoniellagregalis (Distant): Young, 1986: 97.Distribution. India, Myanmar.Atkinsoniellaguttata Kuoh, 1992Atkinsoniellaguttata Kuoh, 1992: 125.Distribution. China .Atkinsoniellaheae Yang, Meng & Li, 2017Atkinsoniellaheae Yang, Meng & Li, 2017: 238.Distribution. China (Tibet).Atkinsoniellaheiyuana Li, 1992Atkinsoniellaheiyuana Li, 1992: 348.Atkinsoniellarubra Kuoh & Cai in Cai & Kuoh, 1994: 14.Distribution. China , Vietnam.Atkinsoniellahuangi Yang & Zhang, 2000Atkinsoniellahuangi Yang & Zhang, 2000: 187.Distribution. China .Atkinsoniellahupehna Young, 1986Atkinsoniellahupehna Young, 1986: 118.Atkinsoniellaobliqua Zhang & Kuoh, 1993: 14.Distribution. China .Atkinsoniellainsignata Tettigoniatrilineata Melichar, 1902: 132.Tettigoniellatrilineatainsignata Haupt, 1924: 306.Tettigellachinensis Metcalf, 1955: 264.Atkinsoniellainsignata (Haupt): Young, 1986: 97.Atkinsoniellalonginotata Kuoh, 1992: 124.Distribution. China .Atkinsoniellajavana Kollajavana Melichar, 1914: 124.Atkinsoniellajavana (Melichar): Young, 1986: 97.Distribution. Indonesia.Atkinsoniellajini Yang, Meng & Li, 2017Atkinsoniellajini Yang, Meng & Li, 2017: 199.Distribution. China (Tibet).Atkinsoniellalatior Young, 1986Atkinsoniellalatior Young, 1986: 113.Distribution. China .Atkinsoniellalii Yang & Zhang, 2000Atkinsoniellalii Yang & Zhang, 2000: 186.Distribution. China (Yunnan).Atkinsoniellalimba Kuoh, 1991Atkinsoniellalimba Kuoh, 1991: 20.Distribution. China (Fujian).Atkinsoniellaliui Yang, Meng & Li, 2017Atkinsoniellaliui Yang, Meng & Li, 2017: 241.Distribution. China (Tibet).Atkinsoniellalonga Yang, Meng & Li, 2017Atkinsoniellalonga Yang, Meng & Li, 2017: 212.Distribution. China (Yunnan).Atkinsoniellalongiaurita Yang, Meng & Li, 2017Atkinsoniellalongiaurita Yang, Meng & Li, 2017: 202.Distribution. China (Yunnan).Atkinsoniellalongiuscula Feng & Zhang, 2015Atkinsoniellalongiuscula Feng & Zhang, 2015: 281.Distribution. China .Atkinsoniellamalaisei Young, 1986Atkinsoniellamalaisei Young, 1986: 102.Distribution. China (Yunnan), Myanmar.Atkinsoniellamediofasciola Yang & Li, 2002Atkinsoniellamediofasciola Yang & Li, 2002b: 40.Distribution. China .Atkinsoniellamembrana Yang, Meng & Li, 2017Atkinsoniellamembrana Yang, Meng & Li, 2017: 213.Distribution. China (Yunnan).Atkinsoniellamotuoensis Meng, Yang & Ni, 2010Atkinsoniellamotuoensis Meng, Yang & Ni, 2010: 47.Distribution. China (Tibet).Atkinsoniellamultiseta Yang, Meng & Li, 2017Atkinsoniellamultiseta Yang, Meng & Li, 2017: 226.Distribution. China (Yunnan).Atkinsoniellamungphuensis Kollamungphuensis Distant, 1908: 225.Atkinsoniellamungphuensis (Distant): Young, 1986: 97.Distribution. India, Myanmar.Atkinsoniellastenopyga Jiang & Yang, sp. nov.Distribution. China (Tibet).Atkinsoniellanigra Kuoh & Cai, 1994Atkinsoniellanigra Kuoh & Cai in Cai & Kuoh, 1994: 13.Distribution. China (Yunnan).Atkinsoniellanigricephala Li, 1992Atkinsoniellanigricephala Li, 1992: 349.Distribution. China .Atkinsoniellanigridorsum Kuoh & Zhuo, 1996Atkinsoniellanigridorsum Kuoh & Zhuo, 1996: 2.Distribution. China .Atkinsoniellanigripennis Yang & Li, 1999Atkinsoniellanigripennis Yang & Li, 1999: 2.Distribution. China (Yunnan).Atkinsoniellanigriscens Yang & Li, 2004Atkinsoniellanigriscens Yang & Li, 2004: 756.Distribution. China .Atkinsoniellanigrisigna Li, 1992Atkinsoniellanigrisigna Li, 1992: 344.Atkinsoniellachloritta Yang & Li, 2002a: 558.Distribution. China .Atkinsoniellanigrita Zhang & Kuoh, 1993Atkinsoniellanigrita Zhang & Kuoh, 1993: 12.Atkinsoniellabimanculata Cai & Shen, 1998: 43.Distribution. China .Atkinsoniellanigrominiatula Cicadellanigrominiatula Jacobi, 1944: 44.Atkinsoniellanigrominiatula (Jacobi): Young, 1986: 97.Distribution. China .Atkinsoniellanigrosteaka Li & Wang, 1994Atkinsoniellanigrosteaka Li & Wang, 1994: 27.Distribution. China (Tibet).Atkinsoniellaopponens Tettigoniaopponens Walker, 1851: 757.Tettigoniellabellona Distant, 1908: 212.Tettigoniellamarpessa Distant, 1908: 215.Kollacanidia Distant, 1908: 226.Kollamaculifrons Schmidt, 1911: 295.Kollamaculifronssimilis Schmidt, 1911: 296.Kollatrimaculata Schmidt, 1911: 297.Tettigoniellacuprea Melichar, 1914: 128.Kollatigrina Distant, 1918: 9.Kollamelichari China, 1935: 305.Atkinsoniellaopponens : Young, 1986: 97.Atkinsoniellatriguttata Zhang & Kuoh, 1993: 9.Distribution. China , India, Indonesia, Laos, Malay Islands, Malaysia, Myanmar, Nepal, Pakistan, Philippines, Thailand, Vietnam.Atkinsoniellapeaka Yang, Meng & Li, 2017Atkinsoniellapeaka Yang, Meng & Li, 2017: 237.Distribution. China (Jiangxi).Atkinsoniellapunica Yang & Li, 2002Atkinsoniellapunica Yang & Li, 2002a: 556.Distribution. China (Yunnan).Atkinsoniellarecta Yang, Meng & Li, 2017Atkinsoniellarecta Yang, Meng & Li, 2017: 209.Distribution. China (Yunnan).Atkinsoniellarectangulata Yang, Meng & Li, 2017Atkinsoniellarectangulata Yang, Meng & Li, 2017: 210.Distribution. China (Yunnan).Atkinsoniellarhomboida Yang, Meng & Li, 2017Atkinsoniellarhomboida Yang, Meng & Li, 2017: 216.Distribution. China (Yunnan).Atkinsoniellarinkihonis Tettigoniarinkihonis Matsumura, 1912: 36.Atkinsoniellarinkihonis (Matsumura): Young, 1986: 97.Curvufaciessordidula Kuoh, 1993: 39.Atkinsoniellatylata Yang & Li, 1999: 1.Distribution. China .Atkinsoniellarubrostriata Kuoh, 1992Atkinsoniellarubrostriata Kuoh, 1992: 123.Distribution. China (Yunnan).Atkinsoniellarufistigma Yang, Meng & Li, 2017Atkinsoniellarufistigma Yang, Meng & Li, 2017: 233.Distribution. China (Yunnan).Atkinsoniellasteelei Young, 1986Atkinsoniellasteelei Young, 1986: 109.Distribution. India.Atkinsoniellasulphurata Tettigoniellasulphurata Distant, 1908: 216.Atkinsoniellamaculata Distant, 1908: 236.Bhandaratetraspila Jacobi, 1944: 41.Atkinsoniellasulphurata (Distant): Young, 1986: 97.Atkinsoniellatetramaculata Zhang & Kuoh, 1993: 7.Atkinsoniellastigma Zhang & Kuoh, 1993: 8.Distribution. China , India, Indonesia, Myanmar.Atkinsoniellathalia Tettigoniellathalia Distant, 1918: 2.Atkinsoniellathalia (Distant): Young, 1986: 97.Atkinsoniellarubrivenosa Kuoh & Zhuo, 1996: 3.Distribution. China , Bay of Bengal, India, Myanmar, Pakistan, Thailand.Atkinsoniellathaloidea Young, 1986Atkinsoniellathaloidea Young, 1986: 117.Distribution. China , Myanmar.Atkinsoniellatiani Yang, Meng & Li, 2017Atkinsoniellatiani Yang, Meng & Li, 2017: 230.Distribution. China (Yunnan).Atkinsoniellatransifasciata Yang, Meng & Li, 2017Atkinsoniellatransifasciata Yang, Meng & Li, 2017: 215.Distribution. China (Yunnan).Atkinsoniellatridentata Yang & Li, 2011Atkinsoniellatridentata Yang & Li in Yang, Meng & Li, 2011: 766.Distribution. China (Yunnan).Atkinsoniellatripunctata Dmitriev, 2020Atkinsoniellatrimaculata Li, 1992: 347.= Atkinsoniellatripunctata Dmitriev, 2020: 7.Distribution. China .Atkinsoniellatuberostyla Yang, Meng & Li, 2017Atkinsoniellatuberostyla Yang, Meng & Li, 2017: 225.Distribution. China (Yunnan).Atkinsoniellauniguttata Li, 1993Atkinsoniellauniguttata Li, 1993: 40.Atkinsoniellavalida Feng & Zhang, 2015: 283.Distribution. China .Atkinsoniellavariata Young, 1986Atkinsoniellavariata Young, 1986: 110.Distribution. China , Nepal.Atkinsoniellavesta Kollavesta Distant, 1908: 224.Atkinsoniellavesta (Distant): Young, 1986: 97.Distribution. India, Pakistan.Atkinsoniellawangi Jiang & Yang, sp. nov.Distribution. China (Tibet).Atkinsoniellawarpa Yang, Meng & Li, 2017Atkinsoniellawarpa Yang, Meng & Li, 2017: 203.Distribution. China .Atkinsoniellawui Yang, Meng & Li, 2017Atkinsoniellawui Yang, Meng & Li, 2017: 200.Distribution. China .Atkinsoniellaxanthoabdomena Yang, Meng & Li, 2017Atkinsoniellaxanthoabdomena Yang, Meng & Li, 2017: 232.Distribution. China (Yunnan).Atkinsoniellaxanthonota Kuoh, 1994Atkinsoniellaxanthonota Kuoh in Cai & Kuoh, 1994: 12.Distribution. China (Yunnan).Atkinsoniellaxanthovena Yang & Li, 2002Atkinsoniellaxanthovena Yang & Li, 2002c: 176.Distribution. China .Atkinsoniellaxanthovitta Kuoh, 1994Atkinsoniellaxanthovitta Kuoh in Cai & Kuoh, 1994: 11.Distribution. China (Yunnan).Atkinsoniellaxinfengi Yang, Meng & Li, 2017Atkinsoniellaxinfengi Yang, Meng & Li, 2017: 223.Distribution. China (Yunnan).Atkinsoniellayani Yang, Meng & Li, 2017Atkinsoniellayani Yang, Meng & Li, 2017: 235.Distribution. China (Yunnan).Atkinsoniellayingjiangensis Jiang & Yang, sp. nov.Distribution. China (Yunnan).Atkinsoniellayunnanana Yang, Meng & Li, 2017Atkinsoniellayunnanana Yang, Meng & Li, 2017: 229.Distribution. China (Yunnan).Atkinsoniellazaihuai Yang & Meng, 2011Atkinsoniellazaihuai Yang & Meng in Yang, Meng & Li, 2011: 766.Distribution. China (Yunnan).Atkinsoniellazhangmuensis Yang, Meng & Li, 2017Atkinsoniellazhangmuensis Yang, Meng & Li, 2017: 227.Distribution. China (Tibet).Atkinsoniellazizhongi Jiang & Yang, 2022Atkinsoniellazizhongi Jiang & Yang in Jiang, Li, Yu & Yang, 2022: 5Distribution. China .


The COVID-19 pandemic highlighted the potential pathogenicity of betacoronaviruses. This elucidates the need to further investigate human coronaviruses (HCoV), which includes both alpha and betacoronaviruses, to better understand their seasonality and severity among children.The New Vaccine Surveillance Network (NVSN) enrolled children at 7 pediatric medical centers in the United States seen at the emergency department (ED) or hospitalized with acute respiratory infection (ARI), during 12/1/2016–9/28/2020. Respiratory specimens were collected and tested using real-time reverse transcription polymerase-chain reaction assays. The frequency of seasonal HCoV  detections was measured and symptoms were reported by parent interview. Descriptive statistics were performed to compare HCoV-positive inpatients to those seen in the ED. SARS-CoV-2 infections were excluded.Of 34,455 children enrolled, 925 (2.7%) were positive for HCoV, of which 398 (43%) were inpatients and (57%) were ED patients (Table). 346 detections (37.4%) were HCoV-OC43, 298 (32.3%) HCoV-NL63, 186 (20.2%) HCoV-HKU1, and 107 (11.6%) HCoV-229E. More than one coronavirus was detected in 12 children (1.3%). HCoV were primarily detected between October and April of each season; 1 to 2 types dominated each year but not consecutively . Among HCoV-positive children, 527 (57.0%) received their highest level of care in the ED while 398 (43.0%) were hospitalized. HCoV-229E was the most common HCoV detected among inpatients (57.0%), followed by HCoV-HKU1-(45.2%); HCoV-OC43- (40.8%); and HCoV-NL63 (38.9%). Among those positive for a HCoV age, race, and insurance status were significantly associated with hospitalization.HCoV followed a winter-season circulation pattern, but with variation in the predominant type across years. HCoV-OC43 accounted for the largest number of HCoV infections whereas HCoV-229E had the highest proportion hospitalized. Further surveillance is required to evaluate the impact of the emergent circulation of SARS-CoV-2 on seasonal HCoVs.Natasha B. Halasa, MD, MPH, Merck: Grant/Research Support|Quidell: Grant/Research Support|Quidell: donation of kits|Sanofi: Grant/Research Support|Sanofi: vaccine support Rangaraj Selvarangan, BVSc, PhD, D(ABMM), FIDSA, FAAM, Abbott: Honoraria|Altona Diagnostics: Grant/Research Support|Baebies Inc: Advisor/Consultant|BioMerieux: Advisor/Consultant|BioMerieux: Grant/Research Support|Bio-Rad: Grant/Research Support|Cepheid: Grant/Research Support|GSK: Advisor/Consultant|Hologic: Grant/Research Support|Lab Simply: Advisor/Consultant|Luminex: Grant/Research Support Geoffrey A. Weinberg, MD, Merck & Co: Honoraria Janet A. Englund, MD, Ark Biopharma: Advisor/Consultant|AstraZeneca: Advisor/Consultant|AstraZeneca: Grant/Research Support|GlaxoSmithKline: Grant/Research Support|Meissa Vaccines: Advisor/Consultant|Merck: Grant/Research Support|Moderna: Advisor/Consultant|Moderna: Grant/Research Support|Pfizer: Advisor/Consultant|Pfizer: Grant/Research Support|Sanofi Pasteur: Advisor/Consultant Pedro A. Piedra, MD, Ark Bioscience: Advisor/Consultant|Ark Bioscience: Grant/Research Support|GSK: Grant/Research Support|Icosavax: Advisor/Consultant|Icosavax: Grant/Research Support|Mapp Biologics: Grant/Research Support|Meissa Vaccines: Grant/Research Support|Moderna: Advisor/Consultant|Novavax: Advisor/Consultant|Novavax: Grant/Research Support|Sanofi-Pasteur: Grant/Research Support|Shionogi: Advisor/Consultant|Shionogi: Grant/Research Support|Takeda: Advisor/Consultant Mary A. Staat, MD, MPH, CDC: Grant/Research Support|Cepheid: Grant/Research Support|Merck: Grant/Research Support|NIH: Grant/Research Support|Pfizer: Grant/Research Support|Up-To-Date: Honoraria John V. Williams, MD, Merck: Grant/Research Support|Quidel: Board Member Marian G. Michaels, MD, MPH, Merck: Grant/Research Support|Viracor: Grant/Research Support


Correction to: BMC Cardiovascular Disorders (2022) 22:56510.1186/s12872-022-02997-9Following publication of the original article [1], the author name “Samuel B. Wopperer” is deleted from the author group.The original article has been corrected.Author details: 1Department of Internal Medicine, MedStar Georgetown University Hospital, 3800 Reservoir Rd NW, Washington, DC 20007, USA


RSV is an extremely common respiratory pathogen and a leading cause of infant hospitalisation. An estimated 1 in 7 infants will develop an RSV lower respiratory tract infection (LRTI) requiring medical attention. The majority of infants hospitalised have no comorbidities and were born at term. Nirsevimab is the only preventative option designed to provide protection to all infants from RSV LRTI, from the start of their first RSV season, for the duration of that season.In the HARMONIE trial conducted in the UK, France, and Germany (EudraCT 2022-000099-20), we evaluated the impact of nirsevimab on all cause LRTI hospitalisations, as well as RSV LRTI specifically. Analyses looked at the efficacy of nirsevimab across subgroups that constitute the all infant population, all of whom are vulnerable throughout their first RSV season.Individually randomised infants  received a single intramuscular injection of nirsevimab , or no intervention (standard of care) before or during the RSV season. Following a single physical visit participants were monitored remotely for all cause LRTI hospitalisation . Efficacy was evaluated through the RSV season. Adverse events (AEs) continue to be monitored for 365 days.8058 infants were randomized, 4037 to the nirsevimab group and 4021 to the no intervention group. Efficacy against RSV LRTI was 83.21% (CI 67.77-92.04%) across all countries. Efficacy was consistent across infant subgroups, in those born at term (≥ 37 weeks: 84.41% (CI 64.92-94.10%)) or prematurely (< 37 weeks: 78.31% (CI 33.49-94.69%)) and not impacted by infant weight at randomisation (< 5kg: 82.12% CI 59.14-93.30% and ≥ 5kg 85.16% CI 57.01-96.25%). Efficacy against all cause LRTI hospitalisation was 58.04% (39.693- 71.19).A single dose of nirsevimab given before or during the RSV season demonstrated a significant and sustained impact on RSV LRTI hospitalisations for the entire RSV season. Consistent efficacy was shown across subgroups comprising the all infant population.The potential impact of nirsevimab was reinforced by a reduction in all cause LRTI hospitalisations.Saul N. Faust, FRCPCH PhD, AstraZeneca, Janssen, Pfizer, Moderna, GlaxoSmithKline, Novavax, Sanofi, Seqirus, Medimmune, Merck, MSD, Iliad and Valneva: Advisor/Consultant|AstraZeneca, Janssen, Pfizer, Moderna, GlaxoSmithKline, Novavax, Sanofi, Seqirus, Medimmune, Merck, MSD, Iliad and Valneva: Investigator Katrina Cathie, MBE, FRCPCH, AstraZeneca: Advisor/Consultant|GSK: Advisor/Consultant|Iliad: Advisor/Consultant|Janssen: Advisor/Consultant|MedImmune: Advisor/Consultant|Merck: Advisor/Consultant|Pfizer: Advisor/Consultant|Sanofi: Advisor/Consultant|Valneva: Advisor/Consultant SB Drysdale, FRCPCH, PhD, AstraZeneca: Advisor/Consultant|iLiAD: Advisor/Consultant|Janssen: Advisor/Consultant|Moderna: Advisor/Consultant|MSD: Advisor/Consultant|Pfizer: Advisor/Consultant|Sanofi: Advisor/Consultant|Valneva: Advisor/Consultant S Royal, FRCGP, Sanofi: Advisor/Consultant C Felter, MD, Sanofi: Employee NC Vassilouthis, MD, Sanofi: Employee Mathieu Bangert, PhD, Sanofi: Staff member K Mari, PhD, Sanofi: Employee R Nteene, MD, Sanofi: Employee M Roberts, MD, Sanofi: Employee P Tissieres, MD, Baxter: Advisor/Consultant|PAion: Advisor/Consultant|Sanofi: Advisor/Consultant|Sedana: Advisor/Consultant


A new device for the removal of cochlear schwannoma: A temporal bone study By Sudhoff S, Riemann C, Kim R, Scholtz LU, Pfeiffer CJ, Goon P and Todt I. (2023) Front. Surg. 10:1077407. doi: 10.3389/fsurg.2023.1077407A corrigendum on Incorrect version: Sudhoff Holger, Riemann Conrad, Kim Rayoung, Lars Uwe Scholtz, Christoph J. Pfeiffer, Goon Peter and Todt Ingo*Correct version: Holger Sudhoff, Conrad Riemann, Rayoung Kim, Lars Uwe Scholtz, Christoph J. Pfeiffer, Peter Goon and Ingo Todt*Incorrect version:Citation: Holger S, Conrad R, Rayoung K, Scholtz LU, Pfeiffer CJ, Peter G and Ingo T (2023) A new device for the removal of cochlear schwannoma: A temporal bone study. Front. Surg. 10:1077407. doi: 10.3389/fsurg.2023.1077407Correct version:Citation: Sudhoff H, Riemann C, Kim R, Scholtz LU, Pfeiffer CJ, Goon P and Todt I (2023) A new device for the removal of cochlear schwannoma: A temporal bone study. Front. Surg. 10:1077407. doi: 10.3389/fsurg.2023.1077407The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.


Correction: Molecular Genetics and Genomics (2023) 298:943–953 10.1007/s00438-023-02027-zIn the published article, in this article reference Ishii et al. 2013 was processed with error and the correct reference should have beenhttps://doi.org/10.1038/ng.2567’.‘Ishii T, Numaguchi K, Miura K, Yoshida K, Thanh PT, Htun TM, Yamasaki M, Komeda N, Matsumoto T, Terauchi R, Ishikawa R, Ashikari M (2013) OsLG1 regulates a closed panicle trait in domesticated rice. Nat Genet 45:462–465. The original article has been updated.


There is an error in reference 30. The correct reference is: Rivers C, Chretien JP, Riley S, Pavlin JA, Woodward A, Brett-Major D, et al. Using "outbreak science" to strengthen the use of models during epidemics. Nat Commun. 2019;10(1):3102. doi: 10.1038/s41467-019-11067-2. PMID: 31308372.


Intradermal testing with COVID-19 mRNA vaccines predicts tolerance By Stehlin F, Mahdi-Aljedani R, Canton L, Monzambani-Banderet V, Miauton A, Girard C, Kammermann K, Meylan S, Ribi C, Harr T, Yerly D and Muller YD. (2022) Front. Allergy 3:818049. doi: 10.3389/falgy.2022.818049An Erratum on Funding section of the original article was made in error. The following sentence has been added: “Open access funding provided by University of Lausanne”.An omission to the The original version of this article has been updated.


Associations of health-related quality of life with major adverse cardiovascular and cerebrovascular events for individuals with ischaemic heart disease: systematic review, meta-analysis and evidence mapping. Open Heart 2023;10:e002452. doi: 10.1136/openhrt-2023-002452.Soloveva A, Gale CP, Han NT, This article has been corrected since it was first published. Author name Han Naung Tun has been corrected.


Correction: BMC Trials 24, 640 (2023)https://doi.org/10.1186/s13063-023-07576-7Following publication of the original article , we haveOriginally published affiliation: “Present address: Statistics & Data Science Innovation Hub, GSK, Brentford, UK”.The original article has been corrected.


This study determined the S. aureus (47.3%). Other organism groups included streptococci (13.6%), enterococci (7.5%), and Enterobacterales (18.5%). MIC testing of OMC and comparators was conducted according to CLSI M07 (2018) and M100 (2023) guidelines. MIC results were interpreted using FDA or CLSI breakpoints.876 bacterial isolates from bone/joint infections were received from 39 medical centers in the USA and 16 European countries (2015–2022). Identifications were confirmed by MALDI-TOF MS. The top BJI pathogen was staphylococci , including in vitro activity against S. aureus  isolates from BJI, including MRSA (96.5%S) and coagulase-negative staphylococci  (Table). All (100%) S. pyogenes , 98.4% of Enterococcus spp. , and 84.9% of other streptococci  were S to OMC, whereas comparator agent susceptibilities ranged from 20.3% to 57.9%S. Against Gram negatives, ≥90.0% of Acinetobacter spp. , Citrobacter spp. , E. coli , Klebsiella spp. , and S. maltophilia  isolates were S to OMC (FDA breakpoints applied to similar organism groups for comparison). Comparator agent susceptibilities ranged from 46.2%S to 100%S against these organism groups.OMC demonstrated potent in vitro activity against staphylococci, streptococci, enterococci, and Gram-negative isolates from bone/joint infections, with activity generally more potent than or equal to the other tetracycline class comparator agents.OMC demonstrated potent Michael D. Huband, BS, BARDA: This study has been funded in part by BARDA under Contract No. 75A50120C00001.|Entasis: Grant/Research Support|Paratek: Grant/Research Support|Pfizer: Grant/Research Support Michael A. Pfaller, MD, Paratek: Grant/Research Support Kelley Fedler, BS, Melinta: Grant/Research Support|Paratek: Grant/Research Support Helio S. Sader, MD, PhD, FIDSA, AbbVie: Grant/Research Support|Basilea: Grant/Research Support|Cipla: Grant/Research Support|Paratek: Grant/Research Support|Pfizer: Grant/Research Support|Shionogi: Grant/Research Support Mariana Castanheira, PhD, AbbVie: Grant/Research Support|Basilea: Grant/Research Support|bioMerieux: Grant/Research Support|Cipla: Grant/Research Support|CorMedix: Grant/Research Support|Entasis: Grant/Research Support|Melinta: Grant/Research Support|Paratek: Grant/Research Support|Pfizer: Grant/Research Support|Shionogi: Grant/Research Support


The correct title is: Usability, acceptability, and self-reported impact of an innovative hepatitis C risk reduction intervention for men who have sex with men: A mixed methods study. The correct citation is: Prinsenberg T, Illidge J, Zantkuijl P, Bedert M, Prins M, van der Valk M, et al. (2022) Usability, acceptability, and self-reported impact of an innovative hepatitis C risk reduction intervention for men who have sex with men: A mixed methods study. PloS ONE 17(2): e0263654.


Doppler Ultrasound of Vascular Complications AfterPediatric Liver Transplantation: Incidence, Time ofDetection, and Positive Predictive ValueMartijn Vincent Verhagen, Ruben H.J. de Kleine, Hubert P.J. vander Doef et al.Ultrasound International Open 2022; 8: 36–4210.1055/a-1961-9100published online: 2022-11-16In the above-mentioned article a specification in Table 2 wasnot correct. The corrected Table 2 is shown below. This wascorrected in the online version on April 14th, 2023.


We evaluated the activity of ceftazidime-avibactam (CAZ-AVI) and aztreonam-avibactam (ATM-AVI) and comparators against common BLs detected in US hospitals.Escherichia coli  and Klebsiella pneumoniae  displaying MIC values ≥ 2 mg/L for at least 2 of the following: ceftazidime, ceftriaxone, aztreonam, or cefepime; (2) Enterobacter cloacae (n=452) and Citrobacter spp. (n=169) displaying MIC values ≥ 16 mg/L for ceftazidime and/or ≥ 2 mg/L for cefepime; and (3) ENT (n=240) displaying elevated carbapenem (meropenem and/or imipenem) MIC results at > 1 mg/L.A total of 21,853 Enterobacterales (ENT) isolates collected during 2020–2021 were susceptibility (S) tested by reference broth microdilution methods. Isolates submitted to whole genome sequencing were: (1) CAZ-AVI inhibited all ESBL-producers  including EC, KPN, and isolates producing CTX-M enzymes (Table). Meropenem-vaborbactam (MEV) inhibited 99.8–100% and ceftolozane-tazobactam (CT) inhibited 67–93.6% of these isolates. ATM-AVI inhibited > 99.4%  of the isolates regardless of the ESBL type or organism. Meropenem S rates against ESBLs ranged from 97.8 to 99.7%. Among other classes, amikacin and tigecycline were the most active agents, inhibiting 78.1% and 97.7% of the ESBL-producing isolates. A total of 97.7% of the isolates had intermediate colistin MIC values. All isolates carrying transferrable AmpC genes were S to CAZ-AVI, ATM-AVI, and MEV and 99.1% were susceptible to meropenem, but only 79.1% were S to CT. These included 82 CMY-producers. Among carbapenemase producers (n=165), CAZ-AVI, ATM-AVI, and MEV susceptibility rates were 81.2%, 98.8% and 80.6%. The only comparator displaying activity against these isolates was tigecycline (93.3% susceptible).Avibactam combinations were active against common BL-producing isolates from US hospitals, including carbapenemase-producing isolates for which therapeutic options are limited. ATM-AVI was the most active agent against carbapenemase-producers when applying the aztreonam breakpoints for comparison.Mariana Castanheira, PhD, AbbVie: Grant/Research Support|Basilea: Grant/Research Support|bioMerieux: Grant/Research Support|Cipla: Grant/Research Support|CorMedix: Grant/Research Support|Entasis: Grant/Research Support|Melinta: Grant/Research Support|Paratek: Grant/Research Support|Pfizer: Grant/Research Support|Shionogi: Grant/Research Support Valerie Kantro, BA, AbbVie: Grant/Research Support|Pfizer: Grant/Research Support|Shionogi: Grant/Research Support Timothy Doyle, MS, AbbVie: Grant/Research Support Rodrigo E. Mendes, PhD, AbbVie: Grant/Research Support|Basilea: Grant/Research Support|Cipla: Grant/Research Support|Entasis: Grant/Research Support|GSK: Grant/Research Support|Paratek: Grant/Research Support|Pfizer: Grant/Research Support|Shionogi: Grant/Research Support Helio S. Sader, MD, PhD, FIDSA, AbbVie: Grant/Research Support|Basilea: Grant/Research Support|Cipla: Grant/Research Support|Paratek: Grant/Research Support|Pfizer: Grant/Research Support|Shionogi: Grant/Research Support


Klebsiella pneumoniae. The PK, safety, and efficacy data of MV in adults support study in pediatrics.The worldwide spread of serine carbapenemases threatens carbapenems. VABOMERE (combination of meropenem and vaborbactam (MV), is a new class of beta-lactamase inhibitors including inhibition of Phase 1, open-label, dose-finding study. Pediatric subjects, 3 mos. to < 18 yrs already on antibiotics received a single-dose weight based infusion of MV over 3 hr. Blood samples were drawn pre-dose, 3,4, and 6 hr. for PK parameters. Population PK model included weight as a covariate. Safety assessments included AEs, vital signs, safety labs, physical exams, infusion tolerance, ECG. A DSMB reviewed safety and PK data before enrolling next cohort.MV was well-tolerated and safe in all age groups. Clearance per kg body weight of both M and V increased with decreasing body weight over all age groups suggesting an allometric relationship.0-8 efficacious in adult trials ranges of 91.7-513 mg•hr/L (meropenem) and 131-494 mg•hr/L (vaborbactam) were achieved in all pediatric cohorts.Targeted AUCPaula M. Bokesch, MD, Melinta Therapeutics: Advisor/Consultant Antonio C. Arrieta, MD, FIDSA, FPIDS, Astellas Pharma Global Development, Inc.: Advisor/Consultant|Astellas Pharma Global Development, Inc.: Grant/Research Support|Astellas Pharma Global Development, Inc.: Honoraria|Cumberland Pharmaceutical: Grant/Research Support|IDbyDNA: Advisor/Consultant|IDbyDNA: Grant/Research Support|Melinta: Grant/Research Support|Merck: Advisor/Consultant|Merck: Grant/Research Support|Nabriva: Grant/Research Support|Paratek Pharmaceuticals: Grant/Research Support|Pfizer, Inc: Advisor/Consultant|Pfizer, Inc: Grant/Research Support|Roche/Genentech: Grant/Research Support|The Medicine Company: Grant/Research Support Randall K. Hoover, Ph.D., Melinta Therapeutics: Advisor/Consultant Sandra McCurdy, MS, Melinta Therapeutics: Employee


UK vaccination programs have reduced COVID-19–related hospitalizations and deaths in the overall population, yet vaccinated individuals with immunocompromised conditions (IC) are still at high risk of severe COVID-19 outcomes. Contemporary evidence on severe outcomes in vaccinated individuals with IC is needed, particularly in the post-pandemic omicron period. Initial results from INFORM, an observational retrospective cohort study describing COVID-19 health burden in individuals with and without IC vaccinated with ≥ 3 doses of a COVID-19 vaccine in England, are presented.Figure 1). The study period was Jan 1, 2022–Dec 31, 2022. Baseline characteristics were identified during the period Jan 1, 2017–Dec 31, 2021. Incidence rates (IR) are presented per 100 person-years (PY).Data from primary and secondary care linked to COVID-19 surveillance, vaccination records, primary care dispensations, and mortality, were accessed via National Health Service (NHS) database (Table 1). Among individuals receiving ≥ 3 vaccine doses, COVID-19 hospitalization IRs were 0.92  in individuals with IC, compared with 0.22 (95% CI: 0.21–0.23) per 100 PY in the overall population. When analyzed by IC type, IRs were higher than the total vaccinated population across all IC subgroups (RR = 2.5–21) (Table 2). COVID-19 hospitalization IRs in patients with hematological malignancies currently under treatment were 4.65 (95% CI: 4.42–4.88) and those with organ transplants were 2.95 per 100 PY (95% CI: 2.7–3.2) (Table 2). Mortality IRs per 100 PY were also consistently higher across all IC groups.Almost 90% of individuals with IC received ≥ 3 vaccine doses compared with 60% in the overall population aged ≥ 12 years (Within a population vaccinated with ≥ 3 doses, individuals with IC had a higher risk of COVID-19 hospitalization and COVID-19 death compared with the overall population. This risk of severe COVID-19 outcomes was elevated across all IC groups, regardless of past or current treatment or procedure despite being vaccinated.Sabada Dube, PhD, AstraZeneca: Employee Yi Lu, PhD, Evidera: Employee Richard McNulty, MD, AstraZeneca: Employee Sophie Graham, MSc, Evidera: Employee Sofie Arnetorp, MS, AstraZeneca: Employee Nahila Justo, PhD, MBA, Evidera: Employee|Karolinska Institute: Employee Renata Yokota, PhD, AstraZeneca: Employee Kathryn Evans, MPH, Evidera: Employee Sudhir Venkatesan, MPH, PhD, AstraZeneca: Employee Mark Yates, PhD, Evidera: Employee Sylvia Taylor, PhD, MPH, MBA, AstraZeneca: Stocks/Bonds Jennifer Quint, PhD, AstraZeneca: Grant/Research Support|Evidera: Grant/Research Support|GlaxoSmithKline: Grant/Research Support|Insmed: Grant/Research Support Rachael A. Evans, PhD FRCP, AstraZeneca: Advisor/Consultant|Boehringer: Advisor/Consultant|Evidera: Advisor/Consultant


Treponema pallidum subspecies pertenue and mainly affects children in tropical countries. A yaws eradication campaign from the 1950s to the early 1960s was successful in reducing cases by 95% worldwide, but a resurgence was noted in the 1970s. In 2012, the World Health Organization (WHO) targeted eradication of yaws through a mass administration of one-dose azithromycin. Nevertheless, in 2021, a total of 123,866 cases were reported from 13 countries, and 1,102 cases from nine countries were confirmed. Confirmed cases were largely from the Western Pacific region, although most cases from this region were not laboratory confirmed . Available from: WHO. Eradication of Yaws—A Guide for Programme Managers. Geneva: World Health Organization; 2018 January 2018. 40 p.10.1371/journal.pntd.0010447.Dofitas BL, Kalim SP, Toledo CB, Richardus JH. Yaws in the Philippines: A clinico-seroprevalence study of selected communities in Mindanao. PLoS Negl Trop Dis. 2022;16(6):e0010447. doi: 10.4269/ajtmh.22-0566. PubMed PMID: 36572006.Dofitas B, Batac MC, Richardus JH. Finding Yaws among Indigenous People: Lessons from Case Detection Surveys in Luzon and Visayas Island Groups of the Philippines. Am J Trop Med Hyg. 2022. Epub 20221226. doi: Boock A, Awah P, Mou F, Nichter M. Yaws resurgence in Bankim, Cameroon: The relative effectiveness of different means of detection in rural communities. PLoS Negl Trop Dis. 2017;11(5):e00005557.


Cabotegravir + rilpivirine (CAB+RPV) administered monthly or every 2 months (Q2M) is the only complete long-acting (LA) regimen for maintaining HIV-1 suppression and may address challenges associated with daily oral therapy. In the Phase 3b SOLAR study, switching to CAB+RPV LA Q2M was noninferior to continuing daily oral bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF). We present results for North American  participants.SOLAR (NCT04542070) is the first randomized (2:1), open-label, multicenter, noninferiority study assessing switching virologically suppressed adults to CAB+RPV LA Q2M  vs. continuing BIC/FTC/TAF. The primary analysis was based on the prespecified modified intention-to-treat exposed (mITT-E) population (n=11 from 1 study site excluded from the ITT-E population for protocol deviation) at Month (M) 12. The primary endpoint was the proportion with plasma HIV-1 RNA ≥50 c/mL. Other endpoints were the proportion with plasma HIV-1 RNA < 50 c/mL, incidence of confirmed virologic failure , safety and tolerability (ITT-E), and treatment satisfaction (HIV Treatment Satisfaction Questionnaire status version [HIVTSQs]).Table 1). At M12, 1 participant in each arm had HIV-1 RNA ≥50 c/mL (Table 2). No NA participant had CVF in the mITT-E population; 1 (0.3%) NA participant excluded from the mITT-E population due to protocol violation had CVF (LA arm). Adverse events (AEs), excluding injection site reactions (ISRs), were similar between the LA (74% [n=164/223]) and BIC/FTC/TAF arms (73% [n=83/113]). More participants in the LA vs. BIC/FTC/TAF arm withdrew due to AEs (8% [n=17/223] vs. < 1% [n=1/113]). Mean adjusted HIVTSQs scores improved significantly (p< 0.001) from BL to M12 for LA (+3.40) vs. BIC/FTC/TAF (–1.07) participants.Of 670 participants (mITT-E), 325 were from North America; 66% (n=216/325) switched to LA and 34% (n=109/325) continued BIC/FTC/TAF. Baseline (BL) characteristics were similar between arms (Consistent with the overall SOLAR study population, switching to CAB+RPV LA from BIC/FTC/TAF was efficacious and well tolerated, with improved treatment satisfaction, in NA participants.Mehri McKellar, MD, Gilead Sciences, Inc: Grant/Research Support Paula Teichner, PharmD, GlaxoSmithKline: Stocks/Bonds|ViiV Healthcare: Employment Jonathan Angel, MD, Gilead: Advisor/Consultant|Gilead: Grant/Research Support|Gilead: Honoraria|Merck: Grant/Research Support|ViiV Canada: Advisor/Consultant|ViiV Canada: Grant/Research Support|ViiV Canada: Honoraria Lori A. Gordon, PharmD, ViiV Healthcare: Stocks/Bonds Kenneth Sutton, MA, ViiV Healthcare: Employment|ViiV Healthcare: Stocks/Bonds Denise Sutherland-Phillips, MD, ViiV Healthcare: Employment|ViiV Healthcare: Stocks/Bonds Christine L. Talarico, M.S., ViiV Healthcare: Stocks/Bonds Rimgaile Urbaityte, MSc, GSK: Employment|GSK: Stocks/Bonds Rodica Van Solingen-Ristea, MD, Janssen R&D: Employee Bryan Baugh, MD, Johnson & Johnson: Stocks/Bonds Ronald D'Amico, DO, MSc, ViiV Healthcare Ltd: Stocks/Bonds Jean A. van Wyk, MBChB, MFPM, ViiV Healthcare Ltd: Stocks/Bonds


BICSTaR is an ongoing, multinational, observational cohort study evaluating the real-world effectiveness and safety of B/F/TAF in antiretroviral therapy (ART) treatment-naïve and treatment-experienced (TE) people with HIV.This analysis of BICSTaR included TE virologically suppressed people with HIV who had started B/F/TAF in clinical practice with/without present/past evidence of HIV drug primary resistance mutations (PRMs). All had viral load (VL) data at baseline (BL). We report virologic and other outcomes at 12 months (M).Table 1).In the overall population, the most common ARTs taken immediately before B/F/TAF were E/C/F/TAF (27%), DTG+F/TAF (9%) and ABC/DTG/3TC (8%). BL genotypic drug resistance testing data were available for 441/996 (44%) participants (ppts); most tests were historic and performed > 60M before starting B/F/TAF  had present/past evidence of PRMs: 13% to NRTI, 11% to NNRTI, 6% to PI, 0.2% to INSTI. The most common PRMs were M184V/I (39 [37%]), ≥ 1 thymidine analog mutation , K103N/S in reverse transcriptase (23 [22%]) and M46I/L in protease (13 [12%]). Primary resistance to > 1 ART drug class was observed in 40 (38%) ppts with PRMs. Ppts with preexisting PRMs were older (≥ 50 years), had more prior ARTs and more prior virologic failure, and had a longer time between HIV diagnosis and starting B/F/TAF versus those without PRMs.Table 2.At 12M, effectiveness  was maintained in 78 (99%) and 739 (98%) ppts with, versus without, any BL PRMs, respectively; 32/33 (97%) of those with M184V/I alone; 13/13 (100%) with M184V/I + 1–2 TAMs; and 2/2 (100%) with M184V/I + ≥ 3 TAMs at BL. No treatment-emergent PRMs to B/F/TAF were reported. Drug-related adverse events (DRAEs) occurred in 17 (16%) ppts with PRMs versus 113 (13%) without PRMs; serious DRAEs occurred in 2 ppts, both had PRMs at BL. Overall, 98/996 (10%) ppts switched from B/F/TAF to other ARTs . Additional outcomes are shown in After 12 months, virologically suppressed people with HIV initiating B/F/TAF in routine clinical practice maintained high rates of effectiveness despite the presence of PRMs (including M184V/I).Benoit Trottier, MD, Gilead: Advisor/Consultant|Gilead: Honoraria|Merck: Advisor/Consultant|Merck: Honoraria|ViiV: Advisor/Consultant|ViiV: Honoraria Fabrice Bonnet, PhD, Gilead: Grant/Research Support|Gilead: Honoraria|Gilead: Educational Miguel Garcia-Deltoro, MD, PhD, AbbVie: Advisor/Consultant|AbbVie: Grant/Research Support|Gilead: Advisor/Consultant|Gilead: Grant/Research Support|Janssen: Board Member|Janssen: Grant/Research Support|MSD: Advisor/Consultant|MSD: Grant/Research Support|ViiV: Advisor/Consultant|ViiV: Grant/Research Support Massimo Andreoni, MD, Gilead: Advisor/Consultant|Moderna: Advisor/Consultant|MSD: Advisor/Consultant Marta Boffito, MD, PhD, FRCP, AstraZeneca: Honoraria|ATEA: Advisor/Consultant|ATEA: Honoraria|Gilead: Advisor/Consultant|Gilead: Grant/Research Support|Gilead: Honoraria|GSK: Advisor/Consultant|GSK: Grant/Research Support|Moderna: Grant/Research Support|MSD: Advisor/Consultant|MSD: Grant/Research Support|MSD: Honoraria|Novavax: Grant/Research Support|Pfizer: Advisor/Consultant|Pfizer: Grant/Research Support|Roche: Advisor/Consultant|Roche: Grant/Research Support|Valneva: Grant/Research Support|ViiV: Advisor/Consultant|ViiV: Grant/Research Support Berend J. van Welzen, MD, PhD, Gilead: Advisor/Consultant|Gilead: Grant/Research Support|ViiV: Advisor/Consultant Dan Turner, MD, Gilead: Advisor/Consultant|Gilead: Honoraria|GSK: Advisor/Consultant|GSK: Honoraria Dai Watanabe, MD, PhD, Gilead Sciences K.K.: Honoraria|Janssen Pharmaceutical K.K.: Honoraria|MSD K.K.: Honoraria|ViiV Healthcare K.K.: Honoraria Alper Gündüz, MD, Gilead: Advisor/Consultant|Gilead: Honoraria|GSK: Advisor/Consultant|GSK: Honoraria|MSD: Advisor/Consultant|MSD: Honoraria David Thorpe, PhD, Gilead: Employment|Gilead: Stocks/Bonds Michelle L. D’Antoni, PhD, Gilead: Employment|Gilead: Stocks/Bonds Tali Cassidy, PhD, Gilead: Employment|Gilead: Stocks/Bonds Andrea Marongiu, PhD, Gilead: Employment|Gilead: Stocks/Bonds Amy R. Weinberg, DNP, MS, Gilead: Employment|Gilead: Stocks/Bonds Richard Haubrich, MD, Gilead: Employment|Gilead: Stocks/Bonds Stefan Scholten, MD, AbbVie: Advisor/Consultant|AbbVie: Honoraria|Cepheid: Grant/Research Support|Cepheid: Honoraria|Gilead: Advisor/Consultant|Gilead: Grant/Research Support|Gilead: Honoraria|Gilead: Congress and travel support|GSK: Grant/Research Support|Janssen: Advisor/Consultant|Janssen: Honoraria|Janssen: Congress support|ViiV: Advisor/Consultant|ViiV: Grant/Research Support|ViiV: Honoraria|ViiV: Congress and travel support


Candida and Aspergillus spp. were identified as the most common causes of invasive fungal infections in COVID-19 patients   , but no Caspofungin is an echinocandin antifungal drug that exerts its antifungal activity by targeting β-D-glucan synthase in the membrane of fungal cells, an enzyme that is absent in the human body . The mecHere we summarize the relationship between COVID-19 and Syk inhibitors. R406, a Syk inhibitor, inhibits both the mainly FcγRIIA-dependent release of proinflammatory cytokines by macrophages and thrombus formation induced by the anti-spike immune complex . R406 inin vitro and in vivo models.In a SARS-CoV-2-specific chimeric antigen receptor (CAR)-T-cell model established to mimic the cytokine storm in COVID-19 patients, caspofungin suppressed inflammatory cytokine production . It alsoCandida and Aspergillus, which are common pathogens associated with COVID-19 (Caspofungin is an antifungal agent with activity against COVID-19 . CaspofuCOVID-19 . AdditioCOVID-19 , which pCOVID-19 . BecauseKI: Conceptualization, Data curation, Formal Analysis, Investigation, Methodology, Project administration, Resources, Validation, Visualization, Writing – original draft, Writing – review & editing. HT: Conceptualization, Methodology, Supervision, Validation, Writing – original draft, Writing – review & editing. YM: Conceptualization, Methodology, Supervision, Validation, Writing – original draft, Writing – review & editing. HI: Conceptualization, Methodology, Project administration, Supervision, Validation, Writing – original draft, Writing – review & editing.


Clinical implications of atrial fibrillation detection using wearable devices in patients with cryptogenic stroke (CANDLE-AF) trial: Design and rationale By Jung S, Lee HA, Kang IS, Shin SH, Chang Y, Woo Shin D, Park M-S, Kim YD, Nam HS, Heo JH, Kim T-H, Yu HT, Lee JM, Heo SH, Woo HG, Park J-K, Roh S-Y, Kim CK, Lee Y-S, Do JK, Kim D-H, Song T-J, Park J and CANDLE-AF Trial Investigators. (2022) Front. Cardiovasc. Med. 9:837958. doi: 10.3389/fcvm.2022.837958A Corrigendum on Incorrect FundingIn the published article, there was an error in the Funding statement. The funding statement for the Korea Medical Device Development Fund grant funded by the Korean government was displayed as . The correct Funding statement appears below.FUNDING(RS-2020-KD000234)] The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.Korea Medical Device Development Fund grant funded by the Korean government [grant number: 9991006899, KMDF_PR_20200901_0234, NTIS, KMDF-RnD 202014X28-00


Genotype-specific ECG-based risk stratification approaches in patients with long-QT syndrome By Rieder M, Kreifels P, Stuplich J, Ziupa D, Servatius H, Nicolai L, Castiglione A, Zweier C, Asatryan B and Odening KE (2022) Front. Cardiovasc. Med. 9:916036. doi: 10.3389/fcvm.2022.916036An Erratum on An omission to the funding section of the original article was made in error. The following sentence has been added: “Open access funding was provided by the University of Bern”.The original version of this article has been updated.


In the manuscript “Tuberculosis and diabetes: association with sociodemographic characteristics and diagnosis and treatment of tuberculosis. Brazil, 2007-2011”, DOI: https://doi.org/10.1590/1980-549720200009, published in the Rev Bras Epidemiol. 2020; 23: E200009:Where it reads:Lúcia Santana RolimIt should read:Lúcia Rolim Santana de Freitas


A blended e-health intervention for improving functional capacity in elderly patients on haemodialysis: A feasibility study By Zemp DD, Baschung Pfister P, Knols R, Quadri P, Bianchi G, Giunzioni D, Lavorato S, Giannini O and de Bruin E. (2022) Front. Digit. Health. 4:1054932. doi: 10.3389/fdgth.2022.1054932An Erratum on Funding section of the original article was made in error. The following sentence has been added: “Open access funding was provided by ETH Zurich”.An omission to the The original article has been updated.


Enterobacterales are increasing in the US. Recommended treatment (tx) options include ceftazidime-avibactam (CZA) plus ATM or FDC. We assessed the in vitro activity of tx options in the setting of a multi-species NDM outbreak.New Delhi metallo-β-lactamase (NDM)-producing Patient isolates were identified through active carbapenemase testing and characterized by whole-genome sequencing. Minimum inhibitory concentrations (MICs) for ATM, ATM-AVI, ceftazidime, CZA, FDC, FDC-AVI, FEP and FEP-TAN were determined by broth microdilution. AVI and TAN were tested at 4 mg/L. Index isolates were defined as the first NDM-producing isolate per species per patient.Table 1) comprising 10 species, the most common species were E. cloacae complex (15), E. coli (3), and K. aerogenes (3). Isolates harbored NDM-5 (72%) or NDM-1 (28%). Other β-lactamases included ACT (15), SHV (7), TEM (7), and CTX-M (6) variants. 93%, 93%, and 69% of index isolates were susceptible to ATM-AVI, FEP-TAN, and FDC, respectively; corresponding MIC50 values were 0.06, 0.5, and 2 mg/L, respectively (Table 2). FDC susceptibility improved to 86% with addition of AVI.48 isolates from 24 patients were included from 2018-2023; 73% of isolates were collected in the last year. 17% of patients were infected with >1 NDM-producing species. Among index isolates . Two patients were treated with CZA-ATM. In 1 case ATM-AVI MICs increased against E. coli from 16 to >128 mg/L post-CZA-AVI tx, attributed to an insertion (YRIN) and substitution (A417V) in ftsI (PBP3). Overall, 4 isolates  from 2 patients were non-susceptible to ATM-AVI, FEP-TAN, and FDC. All were related by WGS and harbored CMY-145, NDM-5, and a YRIN duplication in PBP3.Among serial isolates (n=19), rates of susceptibility were 89%, 84%, and 16% for ATM-AVI, FEP-TAN, and FDC, respectively (in vitro activity against clinical isolates. Susceptibility rates for both β-lactam/β-lactamase inhibitors was higher than FDC, suggesting they may be preferred for tx in the absence of timely susceptibility testing. The activity of each agent is compromised by NDM-producing strains that harbor PBP3 mutations.During a multi-species NDM outbreak we found ATM-AVI and FEP-TAN demonstrated potent Ghady Haidar, MD, Allovir: Grant/Research Support|AstraZeneca: Advisor/Consultant|AstraZeneca: Grant/Research Support|Karius: Advisor/Consultant|Karius: Grant/Research Support|NIH: Grant/Research Support Ryan K. Shields, PharmD, MS, Allergan: Advisor/Consultant|Cidara: Advisor/Consultant|Entasis: Advisor/Consultant|GSK: Advisor/Consultant|Melinta: Advisor/Consultant|Melinta: Grant/Research Support|Menarini: Advisor/Consultant|Merck: Advisor/Consultant|Merck: Grant/Research Support|Pfizer: Advisor/Consultant|Roche: Grant/Research Support|Shionogi: Advisor/Consultant|Shionogi: Grant/Research Support|Utility: Advisor/Consultant|Venatorx: Advisor/Consultant|Venatorx: Grant/Research Support


Correction: Endoscopic treatment for a hematoma-mediated colon obstruction caused by acupuncture: A rare case reportLi S, Sun S, Wang G et al. Endoscopic treatment for a hematoma-mediated colon obstruction caused by acupuncture: A rare case report.Endoscopy 2023 (S1), 55: E713–E714, doi:10.1055/a-2078-0392In the above-mentioned article, the name of Guoxin Wang has been corrected. This was corrected in the online version on May 15, 2023.


Scientific Reportshttps://doi.org/10.1038/s41598-023-38249-9, published online 07 July 2023Correction to: The original version of this Article contained an error in Reference 14, which was incorrectly given as:J. Membr. Sci. Res.3, 25 (2017).Ghasem, N. & Al-Marzouqi, M. Modeling and experimental study of carbon dioxide absorption in a flat sheet membrane contactor. The correct reference is listed below:2 absorption enhancement in hollow-fiber membrane contactors using CNT–water-based nanofluids. J. Membr. Sci. Res. 5, 295–302 (2019).Ghasem, N. Modeling and simulation of COThe original Article has been corrected.


CORAL-CEPI (NCT05435027) is the first test of samRNA-based SARS-CoV-2 vaccines in the African population, under-represented in SARS-CoV-2 vaccine studies. Antibody transience is an issue with first generation SARS-CoV-2 vaccines. This is a preliminary safety and immunogenicity report, showing durable IgG and neutralizing antibody (nAb) responses induced by samRNA vaccine candidates in a South African population.This is an ongoing Phase I, open-label, dose-escalation study of samRNA candidates  encoding full-length Spike  and sequences of Nucleocapsid or selected non-S T cell epitopes (TCEs) . R914  and R912  were administered as 1 or 2 doses in adults (18-65 years) in two cohorts : SARS-CoV-2 anti-N IgG seronegative or seropositive at baseline. Primary objective is safety and secondary objectives assess (at Vismederi srl) S-specific binding IgG (bAb) and nAbs against Beta and Delta variants of concern (VoC) as well as T cell responses against S and additional TCEs.50 against Beta (included in vaccine), and Delta (cross-reactive), at 6 months in Part A, respectively. Antibody responses were durable up to at least 6 months after R914 and up to at least D57 after R912. The majority of subjects who received GRT-R914 had T cell responses to Non-Structural Protein (NSP) and Nucleocapsid antigens. T cell data from subjects vaccinated with GRT-R912 is pending.Most reactogenicities were grade 1 or 2 and transient in nature . Ten out of 180 participants reported grade 3 solicited adverse events which resolved within 1-4 days. 99% of participants showed bAbs > 500 ELU/mL at 6 months, while 79% and 70% participants had nAbs > 500 NDFig.3All doses of R914 and R912 were well-tolerated. Both vaccine candidates increased IgG titers against WT as well as nAb titers against selected VoCs. Antibody levels were durable up to at least 6 months after R914 and 57 days after R912 at all dose levels. Humoral immunity against additional VoCs and additional T cell data will be presented. These results showing similar nAb durability are observed with another samRNA vaccine assessed as boost following primary series with ChAdOx1 or mRNA (NCT05148962).A. Koen, MD, Wits Vaccines & Infectious Diseases Analytics (VIDA) Research Unit, South Africa – Johannesburg (South Africa): Employee E. Mitha, MBChB, Newtown Clinical Research Centre, South Africa - Newtown (South Africa): Employee J. Allagappen, MD, Setshaba Research Centre - Pretoria (South Africa): Employee A. Nagare, MBBS, Gritstone bio, Inc.: Employee|Gritstone bio, Inc.: Stocks/Bonds M. Dhar, MBBS, Shandukani Research - Johannesburg (South Africa): Employee M. Marrali, PhD, Gritstone bio, Inc.: Employee|Gritstone bio, Inc.: Stocks/Bonds Christine Palmer, PhD, Gritstone bio, Inc.: Employee|Gritstone bio, Inc.: Stocks/Bonds Harshni Venkatraman, MS, Gritstone bio, Inc.: Employee|Gritstone bio, Inc.: Stocks/Bonds Jason Jaroslavsky, MS, Gritstone bio, Inc.: Employee|Gritstone bio, Inc.: Stocks/Bonds JC Kuan, PhD, Gritstone bio, Inc.: Employee|Gritstone bio, Inc.: Stocks/Bonds L. Kraemer, PhD, Gritstone: Employee|Gritstone: Stocks/Bonds L. Arcebuche, PhD, Gritstone bio: Employee|Gritstone bio: Stocks/Bonds L. Hernandez, PhD, Gritstone bio: Employee|Gritstone bio: Stocks/Bonds Meghan Hart, ALM, Gritstone bio, Inc.: Employee|Gritstone bio, Inc.: Stocks/Bonds Sonia Kounlavouth, BS, Gritstone bio, Inc.: Employee|Gritstone bio, Inc.: Stocks/Bonds Pedro Garbes, MD, Gritstone bio, Inc.: Employee|Gritstone bio, Inc.: Employee|Gritstone bio, Inc.: Stocks/Bonds|Gritstone bio, Inc.: Stocks/Bonds A. Allen, MBBS, PhD, Gritstone bio, Inc.: Employee|Gritstone bio, Inc.: Ownership Interest|Gritstone bio, Inc.: Stocks/Bonds Karin Jooss, PhD, Gritstone bio: employee|Gritstone bio: Stocks/Bonds Shabhir A. Mahdi, PhD, Wits Vaccines & Infectious Diseases Analytics (VIDA) Research Unit, South Africa – Johannesburg (South Africa): Employee


Sugiyarto G, Lau D, Hill SL, et al. Reactivation of low avidity tumor-specific CD8+ T cells associates with immunotherapeutic efficacy of anti-PD-1. Journal for ImmunoTherapy of Cancer 2023;11:e007114. doi: 10.1136/jitc-2023-007114The author Tim Elliott has been made a corresponding author and Eileen E Parkes was incorrectly listed as Eileen Parkes. The third affiliation has been updated to Department of Oncology, University of Oxford, Oxford, UK.


P=0.212; median follow-up: 183 days) and was well tolerated. We report final safety data from STORM CHASER.In the STORM CHASER phase 3 post-exposure prophylaxis study, 300-mg intramuscular (IM) AZD7442 (tixagevimab/cilgavimab) reduced symptomatic COVID-19 by 33.3% vs placebo at primary analysis (In STORM CHASER (NCT04625972), adults without prior SARS-CoV-2 infection or COVID-19 vaccination were enrolled within 8 days of exposure to a SARS-CoV-2–infected individual and randomized 2:1 to receive a single intramuscular dose of 300-mg AZD7442 (N=749) or placebo (N=372). Results are reported from the November 12, 2022 final data cut-off. The primary safety endpoint was assessment of adverse events (AEs), serious adverse events (SAEs), medically attended AEs (MAAEs), and AEs of special interest (AESIs). AESIs included injection site and hypersensitivity reactions. Efficacy data have previously been reported.Table). Most AEs were mild to moderate in severity; 30 (4.0%) and 26 (7.0%) of participants in the AZD7442 and placebo groups, respectively, reported an AE of grade 3 (severe) or higher. SAEs occurred in 2.7% and 4.3% of AZD7442 and placebo participants, MAAEs in 12.7% and 14.0%, AESIs in 0.5% and 1.1%, and deaths in 0.4% and 0.5%, respectively.Across both the AZD7442 and placebo groups, 928 (82.1%) participants completed the study. Median follow-up was 455 days (∼15 months) in both groups. AEs occurred in 46.5% and 51.9% of participants administered AZD7442 and placebo, respectively (These findings support the long-term safety of AZD7442.Myron J. Levin, MD, Dynavax: Advisor/Consultant|GSK: Advisor/Consultant|GSK: Grant/Research Support|GSK: Data safety monitoring/Advisory board|Johnson & Johnson: Grant/Research Support|Merck & Co.: Advisor/Consultant|Moderna: Grant/Research Support|Novavax: Grant/Research Support|Pfizer: Advisor/Consultant|Seqirus: Advisor/Consultant Andrew Ustianowski, MD, PhD, Gilead: Honoraria|Gilead: Advisory Board|GSK: Honoraria|Janssen: Honoraria|Merck: Honoraria|Merck: Advisory Board|Sanofi: Honoraria|ViiV Healthcare/GSK: Advisory Board Jesse Thissen, MSc, AstraZeneca: Employee|AstraZeneca: Stocks/Bonds Seth Seegobin, PhD, AstraZeneca: Employee|AstraZeneca: Stocks/Bonds Rohini Beavon, PhD, AstraZeneca: Employee|AstraZeneca: Stocks/Bonds Kanika Dey, MSc, AstraZeneca: Employee|AstraZeneca: Stocks/Bonds Elizabeth J. Kelly, PhD, AstraZeneca: Employee|AstraZeneca: Stocks/Bonds Karen A. Near, MD, AstraZeneca: Employee|AstraZeneca: Stocks/Bonds Katie Streicher, PhD, AstraZeneca: Employee|AstraZeneca: Stocks/Bonds Alexandre Kiazand, MD, AstraZeneca: Employee|AstraZeneca: Stocks/Bonds Mark T. Esser, PhD, AstraZeneca: Employee|AstraZeneca: Stocks/Bonds


The correct spelling is: Khabir Ahmad. The correct citation is: Bin Helayel H, Ahmed A, Ahmad K, Ahmad A, Khan R, Al-Swailem SA (2022) Quarantine-related traumatic stress, views, and experiences during the first wave of Coronavirus pandemic: A mixed-methods study among adults in Saudi Arabia. PloS ONE 17(1): e0261967.


Enterococcus (ENT) and resistant (R) subsets from US medical centers was evaluated comparatively between 2022 and 2017–2019.A new formulation of oritavancin (ORI) to be infused over 1 hour for the treatment of skin and skin structure infections was approved in 2021 by the US FDA. The activity of ORI and its comparators against E. faecalis (EF) from 2022 and 2017–2019, respectively, 148/1,348 E. faecium (EFM), and 14/150 other ENT were collected (1/patient) from 34 US medical centers. Isolates were identified by MALDI-TOF MS and standard microbiology tests and susceptibility (S) tested by CLSI broth microdilution. CLSI clinical breakpoints (BPs) and VanA/VanB phenotypes were used. ORI BPs against vancomycin (VAN)-S EF were applied to all ENT.4,462 ENT, including 246/2,556 50/90, 0.015/0.03 mg/L) was similar to 2017–2019 . ORI inhibited 97.5%/98.9% of ENT from 2022/2017–2019 at ≤ 0.12 mg/L. VAN and linezolid (LZD) inhibited 97.2%/98.4% and 99.6%/99.6% of ENT from 2022/2017–2019, at the respective BPs. ORI, VAN, LZD and daptomycin (DAP) showed stable S rates ( > 96%) against EF. ORI remained active against 57.1/53.1% of VAN-R EF. VanA rates in VAN-R EF from 2022 and 2017–2019 were 85.7%/93.8%. ORI inhibited the 3 VanB EF isolates at ≤ 0.03 mg/L. LZD and DAP remained active against VAN-R EF (100%). Similar activity was noted for ORI against EFM from 2022  and 2017–2019 . The EFM S rate to VAN was 35.1% in 2017–2019 and 39.2% in 2022. The S rates to ORI (VAN-S EF BPs) and LZD remained stable ( > 98%) as well as rates of DAP susceptible dose-dependent . The VanB phenotype increased from 7.8% in 2017–2019 to 20.0% in 2022. ORI inhibited all VanB and 98.5% of VanA EFM at ≤ 0.12 mg/L. LZD inhibited 98.6%/99.4% of VanA EFM isolates in 2022/2017–2022. The DAP SDD rate slightly decreased against VanA EFM (99.7% to 93.1%). ORI and comparators were active against other ENT.ORI activity against ENT from 2022 (MICORI exhibited potent and stable activity against ENT clinical isolates, including VAN-R EFM in US. An increase in VanB EFM phenotype and a slight decrease in the DAP SDD rates in VAN-R EFM subsets were noted over time.Cecilia G. Carvalhaes, MD, PhD, AbbVie: Grant/Research Support|bioMerieux: Grant/Research Support|Cipla: Grant/Research Support|CorMedix: Grant/Research Support|Melinta: Grant/Research Support|Pfizer: Grant/Research Support Rodrigo E. Mendes, PhD, AbbVie: Grant/Research Support|Basilea: Grant/Research Support|Cipla: Grant/Research Support|Entasis: Grant/Research Support|GSK: Grant/Research Support|Paratek: Grant/Research Support|Pfizer: Grant/Research Support|Shionogi: Grant/Research Support Dee Shortridge, PhD, Melinta: Grant/Research Support|Shionogi: Grant/Research Support Mariana Castanheira, PhD, AbbVie: Grant/Research Support|Basilea: Grant/Research Support|bioMerieux: Grant/Research Support|Cipla: Grant/Research Support|CorMedix: Grant/Research Support|Entasis: Grant/Research Support|Melinta: Grant/Research Support|Paratek: Grant/Research Support|Pfizer: Grant/Research Support|Shionogi: Grant/Research Support


Correction: Reprod Biol Endocrinol 20, 28 (2022).10.1186/s12958-022-00892-8.Following publication of the original article , the autSills ES, Wood SH. Autologous activated platelet-rich plasma injection into adult human ovary tissue: Molecular mechanism, analysis, and discussion of reproductive response. Biosci Rep. 2019;39(6):BSR20190805. 10.1042/BSR20190805.The original article  has been


Objective: describe epidemiology and variations of the cases notified in Uruguay between 1.1.2008 and 12.31.2021 according vaccine strain.In Uruguay varicella is mandatory notification disease since 1963. Universal vaccination starts in 1999 (OKA strain 1 dose) when incidence was 105/100.000 inhab; in 2014 2Observational, descriptive, retrospective study. All cases reported to the Department of Health Surveillance (DEVISA)-Epidemiology Division-Ministry of Health in period: 1.1.08 to 12.31.21. Data source: DEVISA and Honorary Commission-Fight Against TB-Prevalent Diseases. Variables: notified cases, average annual incidence, age, sex, outbreaks. Vaccine: doses, OKA or MAV/06 strain Statistical analysis: frequency distribution, summary measures and statistical significance tests  4 periods according vaccine strain in nation immunization program were defined: 2008 and 2009 (Oka), 2010 to 2012 (Oka and MAV06); 2013 to 2018 (MAV) and 2019 to 2021 (OKA)Accumulated cases: 13,896 . Women: 6639 (48%) Vaccine coverage was around 95-97%. Incidence: 32.2/100,000/inhabitants (95%CI:30-34) in 2008-2009, the rate decrease in 2010-2012 to 21.5 (19-13), in 2013-2018 increased 35,78 (35-36), in this period in 2013, 1968 cases was reported. Rate in 2019-2021: 12 (11-12) , with 2 doses of vaccine. There wasn’t a significant difference in annual average cases (AANC) 2008-2013 (AANC: 1025) vs 2014-2018 (AANC: 1293) p=0,345. The AANC in 2019-2021 were 424. . There was a significant increase in the annual average of outbreaks 30/2012-2013 vs. 90/2014-2018. In 2019:81, 2020:10 and 2021:7 outbreaks. Between 2008-2018 most cases were reported in the group 10 to 14 years of age (median 187.5m); 2019-2021, 678/1,272 cases were older than 12Incidence dropped from 105 in 1999 to 24 in 2019. There was a displacement to older ages. The 2nd dose didn’t change incidence and outbreaks frequency. The incidence decreased in 2019-2021. Surely the great decrease in the incidence and outbreaks in 2020 and 2021 was influenced by COVID-19 pandemic. Since 2010 to 2018, the most widely used vaccine contained MAV/06Marcos Delfino, Pediatrician, pediatric infectologist, Adjunct Professor of pediatric clinic, Pfizer: Finnancial support to travel to IDWeek 2023 Ignacio Olivera, Medical Doctor, Master in Health Economics and Pharmaceutical Economics, Pfizer: Grant/Research Support|Roche: Expert Testimony|Sanofis Pasteur: Grant/Research Support María Catalina Pírez, Pediatrician, Pediatric infectologist, microbiologist Professor of pediatric, Degree V, Merck, Pfizer: Expert Testimony|Merck, Pfizer: Honoraria